1. Home
  2. STRW vs AGEN Comparison

STRW vs AGEN Comparison

Compare STRW & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Strawberry Fields REIT Inc.

STRW

Strawberry Fields REIT Inc.

HOLD

Current Price

$13.25

Market Cap

171.8M

Sector

Real Estate

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.18

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRW
AGEN
Founded
2015
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.8M
147.4M
IPO Year
2019
1999

Fundamental Metrics

Financial Performance
Metric
STRW
AGEN
Price
$13.25
$3.18
Analyst Decision
Buy
Buy
Analyst Count
3
2
Target Price
$13.88
$14.50
AVG Volume (30 Days)
14.9K
816.4K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
5.17%
N/A
EPS Growth
5.26
100.00
EPS
0.17
1.02
Revenue
$154,999,000.00
$42,877,086.00
Revenue This Year
$8.52
$107.63
Revenue Next Year
$3.95
N/A
P/E Ratio
$77.71
$3.09
Revenue Growth
32.41
89.95
52 Week Low
$9.46
$2.71
52 Week High
$14.00
$7.34

Technical Indicators

Market Signals
Indicator
STRW
AGEN
Relative Strength Index (RSI) 57.95 38.93
Support Level $12.51 $2.91
Resistance Level $13.36 $3.26
Average True Range (ATR) 0.37 0.26
MACD 0.03 -0.08
Stochastic Oscillator 83.95 11.99

Price Performance

Historical Comparison
STRW
AGEN

About STRW Strawberry Fields REIT Inc.

Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: